Intellectual Property Approach
We are creating a highly commercializable IP portfolio of therapeutics for treating addiction.
To do so we are conducting ongoing clinical research programmes on ketamine and MDMA-assisted therapies, as well as creating and trialling a pipeline of novel patentable drugs with improved properties for treating addiction.
Our Therapy and Drug Development Pipeline
Therapeutics Development Strategy
The purpose of our R&D program is to develop world-leading therapeutics to treat addiction.
Sign Up for Newsletter